Inventprise

Ondine Biomedical Inc. is a Canadian life sciences company that has emerged as a global leader in photodisinfection-based therapies for preventing and treating a wide range of infections, including those caused by drug-resistant pathogens. Their patented platform technology offers solutions for infections in healthcare and industrial settings, with recent studies demonstrating up to an 84% reduction in postoperative infection rates in major Canadian hospitals. Their flagship product, Steriwave, is a rapid nasal decolonization therapy that effectively eradicates a broad spectrum of pathogens in just minutes, significantly reducing the risk of healthcare-associated infections. Ondine Biomedical is dedicated to developing innovative products to combat antimicrobial resistance and improve patient outcomes, with a focus on safe, fast, and cost-effective solutions for complex infections. Generated from the website

Nanostring Technologies, based in Seattle, WA, is a leading provider of innovative solutions for spatial molecular imaging and single-cell research. Their cutting-edge products, such as the CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler, empower researchers to uncover unprecedented biological insights at single-cell resolution. With a focus on accelerating drug development, biomarker discovery, and gene expression profiling, Nanostring Technologies offers comprehensive research solutions like the nCounter Analysis System and AtoMx Spatial Informatics Platform. Their advanced technologies and platforms enable scientists to gain deeper insights into spatial multiomics data and drive impactful discoveries in fields ranging from oncology to regenerative medicine.Generated from the website

Syntrix Pharmaceuticals is a leading biopharmaceutical company based in Auburn, WA, specializing in the development of breakthrough medicines. With a strong focus on immuno-oncology and pain research, Syntrix is dedicated to advancing innovative therapies that have the potential to transform patient outcomes. Driven by a convergent science strategy, Syntrix's pipeline of hope includes promising candidates such as SX-682, which has shown great potential in enhancing the effectiveness of therapies targeting the RAS RAF MEK ERK signaling pathway in non-small cell lung cancer. Committed to corporate responsibility, Syntrix is at the forefront of developing novel strategies to combat cancer and improve the lives of patients worldwide.Generated from the website